Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MAFG-AS1/PCBP2/FPN1 regulation axis as target site detection reagent in preparation of medicine for treating bladder cancer

A detection reagent, FPN1 technology, applied in the field of biomedicine, can solve the problem of unclear effect of bladder cancer, and achieve the effect of improving treatment and survival, and inhibiting drug resistance

Active Publication Date: 2020-02-18
THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

MAFBZIP Transcription Factor G Antisense RNA 1 (MAFG-AS1) is the latest reported lncRNA that can promote tumor proliferation and metastasis, but the role of MAFG-AS1 in bladder cancer is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MAFG-AS1/PCBP2/FPN1 regulation axis as target site detection reagent in preparation of medicine for treating bladder cancer
  • Application of MAFG-AS1/PCBP2/FPN1 regulation axis as target site detection reagent in preparation of medicine for treating bladder cancer
  • Application of MAFG-AS1/PCBP2/FPN1 regulation axis as target site detection reagent in preparation of medicine for treating bladder cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] Below in conjunction with accompanying drawing and experimental data, the present invention is further explained and illustrated

[0020] 1. Materials and methods

[0021] Cell culture and transfection, qRT-PCR analysis, RNA purification and separation of chromatin (CHIRP), parallel reaction monitoring (PRM), Western blot analysis, immunohistochemistry assay, MTT assay, flow cytometry, immunoprecipitation, chromatin immunoassay Co-precipitation, immunofluorescence, dual luciferase assay, iron colorimetry, malondialdehyde (MDA) assay, flow cytometry assay for Lipid-ROS, colony formation assay, the above methods are all existing methods and will not be repeated here Tired.

[0022] ,result

[0023] 2.1 MAFG-AS1 can inhibit the ferroptosis of bladder cancer cells

[0024] We knocked out and overexpressed MAFG-AS1 in T24 / RT4 cell lines respectively ( figure 1 G, H), MTT experiments further confirmed that the cell proliferation ability was significantly inhibited after M...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of an MAFG-AS1 / PCBP2 / FPN1 regulation axis as a target site detection reagent in preparation of a medicine for treating the bladder cancer. The research proves that MAFG-AS1 with the increased expression is combined with PCBP2 in a bladder cancer cell and then a deubiquitination enzyme UCHL5 is recruited to stabilize the expression of the PCBP2, iron ions aretransferred to FPN1 on a cell membrane under the transportation effect of the PCBP2 to promote transferring of iron out of the cell so as to cause iron death resistance. Therefore, the existence of the MAFG-AS1 / PCBP2 / FPN1 regulation axis in the bladder cancer is proved for the first time and the regulation axis is a valuable potential therapeutic drug in the field of bladder cancer treatment. Andthus the PCBP2 can be used as a target site in the preparation of a medicament for treating the bladder cancer and is also a molecular marker for clinically predicting a bladder cancer patient.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of "MAFG / AS1 / PCBP2 / FPN1" regulation axis and PCBP2 as a target site detection reagent in the preparation of drugs for treating bladder cancer. Background technique [0002] Cisplatin (DDP) is a first-line chemotherapy drug for the treatment of bladder cancer. DDP mainly acts on the purine and pyrimidine bases of cellular DNA, forms cisplatin-DNA adducts with DNA, causes DNA damage, inhibits DNA replication and transcription, and then kills tumor cells. In recent years, the resistance of bladder cancer cells to cisplatin has seriously affected the curative effect of cisplatin. At present, it is generally believed that the mechanism of cisplatin resistance mainly exists in two aspects: the reduction of tumor cell DNA damage is based on the reduction of cisplatin binding to DNA; the damaged DNA is repaired by the DNA repair system and the cell death e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/574
CPCG01N33/6872G01N33/57407G01N33/57484G01N2500/00
Inventor 曹科向亮肖梦卿何东朱煜星曾庆海
Owner THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com